Skip to main content
. 2021 May 28;15(1):148. doi: 10.3892/mco.2021.2310

Figure 2.

Figure 2

KRAS mutations contributed to anti-EGFR antibody drug resistance in CACO-2 cells. (A) The RPR with cetuximab administration was significantly elevated in all KRAS G12D, G12V, G13D, G12A, G12C, G12S, Q61H and A146T mutants. (B) Similar results were obtained following the administration of panitumumab. **P<0.01 vs. drug-free control. KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; RPR, relative proliferation ratio.